^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ER positive

    i
    Other names: ESR1, Era, ESR, NR3A1, ER, ER beta
    Entrez ID:
    2099
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    1d
    Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer (clinicaltrials.gov)
    P3, N=246, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Active, not recruiting --> Recruiting | Trial completion date: Mar 2031 --> Jun 2029 | Trial primary completion date: Sep 2030 --> Dec 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • ER negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Halaven (eribulin mesylate)
    2d
    Doxorubicin plus anlotinib for the adjuvant treatment of stage I–II high-grade uterine sarcoma: a single-arm exploratory study (ChiCTR2600121235)
    P=N/A, N=43, Obstetrics and Gynecology Hospital Affiliated to Fudan University; Obstetrics and Gynecology Hospital Affiliated to Fudan University
    New trial
    |
    ER (Estrogen receptor)
    |
    ER positive
    |
    Focus V (anlotinib) • doxorubicin hydrochloride
    2d
    A single-arm, phase II, exploratory study of neoadjuvant treatment with Kudosil combined with Culmerciclib and dual-targeted therapy of trastuzumab and pertuzumab in HR+, HER2+ breast cancer (ChiCTR2600121242)
    P2, N=28, Recruiting, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital); The First Affiliated Hospital of Nanjing Medical U
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER positive
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • letrozole • Saitanxin (culmerciclib)
    2d
    A Prospective, Cohort, Open Study of Immunoradiotherapy Combined with Cidarbenamide and PD-1 Monotherapy in the Backline Treatment of Advanced Solid Tumors (ChiCTR2300068737)
    P4, N=67, Recruiting, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School; Nanjing Drum Tower Hospital, The Affiliated Hospital of Nan | Not yet recruiting --> Recruiting | Phase classification: PN/A --> P4 | N=35 --> 67
    Enrollment open • Phase classification • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Tyvyt (sintilimab) • Epidaza (chidamide)
    3d
    Integrin Beta 4 Protein Expression Bimodally Predicts Sensitivity to CDK4/6 Inhibition and Resistance to Immunotherapy in Breast Cancer. (PubMed, Breast J)
    ITGB4 protein expression serves as a bimodal biomarker in breast cancer, predicting CDK4/6 inhibitor sensitivity in luminal subtypes while indicating immunotherapy resistance in TNBC. ITGB4 protein thus represents a critical biomarker for guiding personalized therapy in precision oncology.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PD-L2 (Programmed Cell Death 1 Ligand 2) • ITGB4 (Integrin Subunit Beta 4) • MIR342 (MicroRNA 342)
    |
    PD-L1 expression • ER positive
    3d
    Associations of reproductive history with serum and intratumoral sex steroid hormone levels among postmenopausal women with breast cancer: Analysis of paired serum and tumor tissue samples. (PubMed, Maturitas)
    Reproductive history, particularly breastfeeding, may be associated with intratumoral estradiol levels in postmenopausal women with estrogen receptor-positive breast cancer. These findings suggest the importance of considering reproductive factors when investigating biological mechanisms underlying breast cancer progression and prognosis.
    Journal
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • ER negative
    3d
    The role of stereotactic body radiotherapy in oligoprogressive breast cancer: A site-specific analysis of the prospective, phase-II RADIANT trial. (PubMed, Clin Transl Radiat Oncol)
    Among this cohort of patients with oligoprogressive breast cancer, SBRT is a safe and promising intervention, with potential to delay next-line systemic therapy. However, as a significant cohort of patients do require a change in systemic therapy within 1-2 years of SBRT, biomarkers are needed to best select patients who would benefit clearly from this approach.
    P2 data • Journal
    |
    ER (Estrogen receptor)
    |
    ER positive
    3d
    Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (clinicaltrials.gov)
    P3, N=315, Active, not recruiting, AstraZeneca | Trial completion date: Nov 2027 --> Sep 2028
    Trial completion date • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HR positive • HER-2 negative • ESR1 mutation • HR positive + HER-2 negative • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation • HER-2 negative + HR positive + ESR1 mutation
    |
    Guardant360® CDx
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • letrozole • anastrozole • camizestrant (AZD9833)
    3d
    Independent, External, Blinded Retrospective Validation of an AI-based Prognostic Assay in ER-Positive/HER2-Negative Early Breast Cancer (clinicaltrials.gov)
    P=N/A, N=2200, Active, not recruiting, Spotlight Medical
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive
    4d
    ADAPTela: Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC (clinicaltrials.gov)
    P3, N=1520, Not yet recruiting, West German Study Group | N=1050 --> 1520
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CDK4 (Cyclin-dependent kinase 4)
    |
    ER positive • HR positive • HER-2 negative • HER-2 negative + ER positive
    |
    MammaPrint® • Oncotype DX Breast Recurrence Score®Test
    |
    Kisqali (ribociclib) • Orserdu (elacestrant)
    4d
    Level of estrogen receptor expression, histological grade, and computationally assessed stromal TILs on pre-treatment biopsies predict pathological complete response to neoadjuvant chemotherapy in ER-positive/HER2-negative breast cancer. (PubMed, Virchows Arch)
    Response to NACT is strongly influenced by ER expression, tumor grade, and sTIL levels. Composite profiles combining these factors can help identify patients most likely to achieve meaningful response, while also highlighting subgroups with low benefit where alternative treatment strategies may be more appropriate.
    Journal • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive